C O V E R S T O R Y
we started with a small prescriber base , today we have more than 12,000 clinicians and 4000 hospitals in our network . We are growing these relationships steadily based on trust and credibility of the brand .”
“ Our diagnostics business has steadily grown over the past few years , and we now have over 60 % of the NGS testing market in India . We cover all the major disease areas and have been increasing our geographic footprint across the country with a strong salesforce of more than 200 across India , dedicated to the respective segments . We have also successfully expanded to neighbouring countries such as Sri Lanka , Bangladesh , Malaysia , Middle East , Africa ,” adds Pratapneni .
It took a while for the company to spread the awareness on the fact that genetic diagnostic tests are specialized tests and do not replace any of the existing diagnostic tests . And also that these tests can in fact provide new benefits in understanding the cause of the disease or in choosing the right treatment or for avoiding an unnecessary invasive procedure and can thus help save treatment costs and time significantly .
Key milestones
MedGenome being a pioneer in this field has many firsts to its credit . MedGenome was the first to bring Non-invasive Prenatal Testing to India validated by an India based study . It was also the first to launch Liquid
Biopsy and clinical exomes for rare genetic disorders . Our SPIT Seq whole genome sequencing based test for TB is the first of its kind test which can identify MDR TB accurately at a quicker turnaround time than the current available tests . Our proprietary in-house database and AI / ML enabled bioinformatic suites strengthened us with data-driven insights and helped us in launching our preventive wellness testing category . It has developed Polygenic Risk Score ( PRS ) based genetic screening tests in our wellness portfolio which assess genetic risk of lifestyle diseases , such as Kardiogen test for heart health , Diabetogen for diabetes , Hypersense for hypertension and Neurosense for Parkinson ’ s and Alzhimer ’ s disease and many more .
MedGenome has made significant advances in scientific research , particularly in coronary artery disease , diabetes , and Parkinson ' s disease etc . with over 100 publications in leading scientific journals . It is set to unveil the outcomes of a comprehensive analysis of 60,000 non-invasive prenatal tests ( NIPT ) with an impressive accuracy rate of approximately 99.3 %, serving as a benchmark for the diagnostic community . Team has worked with oncologists to build a dataset of over 3000 lung cancer patients , revealing prevalent genetic mutations in Indian patients , guiding tailored treatment approaches .
The company is one of the founding
16
BioVoiceNews | March / April 2024